NCT03498430View on ClinicalTrials.gov

Copanlisib Chinese PK Study

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

April 27, 2018

Primary Completion Date

August 6, 2019

Study Completion Date

June 2, 2020

Conditions
Lymphoma, Non-Hodgkin
Interventions
DRUG

Copanlisib (Aliqopa, BAY80-6946)

Copanlisib will be administered intravenously on 60mg once in a 3 weeks-on/1 week-off dose regimen (on Days 1, 8 and 15)

Trial Locations (1)

100142

Beijing Cancer Hospital, Beijing

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT03498430 - Copanlisib Chinese PK Study | Biotech Hunter | Biotech Hunter